Christina Coughlin named chief medical officer of Immunocore Ltd.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CHRISTINA COUGHLIN was named chief medical officer of Immunocore Ltd.

Most recently, Coughlin was leading two early development programs at Novartis in checkpoint inhibition and PI3 kinase inhibition. She led the overall program early development teams, including preclinical pharmacology, toxicology, clinical pharmacology, clinical development, biomarker development and regulatory work.

Before that, she served as international project team leader at Morphotek Inc., where she led the early clinical development team responsible for monoclonal antibody development against novel targets.

YOU MAY BE INTERESTED IN

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login